Articles & Guides

Educational resources for peptide research

Stay informed with our collection of articles covering peptide reconstitution, dosing protocols, and the latest research findings.

Guide8 min read
Peptide Reconstitution Guide
Learn how to reconstitute lyophilized peptides with step-by-step instructions, troubleshooting tips to prevent gelling, and a simple dosage calculator.
Research6 min read
What is Retatrutide?
Discover what Retatrutide is, how it works in metabolic research, key study insights, and why it's gaining attention as a novel investigational peptide.
Guide5 min read
Practical Injection Tips
Optimize injection methods, site rotation, and comfort for subcutaneous peptide administration.
Coming Soon
Guide

Peptide Reconstitution Guide

A comprehensive guide to properly reconstituting lyophilized peptides for research applications.

What You'll Need

  • Bacteriostatic water (BAC water) - contains 0.9% benzyl alcohol as preservative
  • Sterile insulin syringes (U-100, 29-31 gauge)
  • Alcohol swabs for sanitization
  • Your lyophilized peptide vial

Step-by-Step Process

  1. 1

    Prepare Your Workspace

    Clean your work surface with alcohol. Wash hands thoroughly or wear clean gloves. Ensure all materials are within reach.

  2. 2

    Allow Temperature Equilibration

    Remove the peptide vial from storage and allow it to reach room temperature (15-20 minutes). This prevents condensation inside the vial.

  3. 3

    Sanitize the Vial Tops

    Wipe the rubber stopper of both the peptide vial and BAC water vial with an alcohol swab. Allow to air dry.

  4. 4

    Draw the BAC Water

    Using a sterile syringe, draw your calculated amount of bacteriostatic water. Common amounts are 1-2 mL depending on desired concentration.

  5. 5

    Inject Slowly

    Insert the needle into the peptide vial at an angle, aiming at the glass wall. Inject the water slowly, allowing it to run down the side. Never spray directly onto the powder.

  6. 6

    Dissolve Gently

    Gently swirl or roll the vial to dissolve the powder. NEVER shake vigorously as this can damage the peptide structure. Most peptides dissolve within 1-2 minutes.

  7. 7

    Inspect the Solution

    The solution should be clear or slightly opalescent. If you see particles or cloudiness that doesn't clear, the peptide may be damaged.

  8. 8

    Label and Store

    Label the vial with the date, concentration, and peptide name. Store immediately in the refrigerator at 2-8°C.

Troubleshooting: Preventing Gelling

Some peptides (especially BPC-157 and certain blends) can gel if reconstituted improperly. To prevent this:

  • Always inject water slowly down the vial wall
  • Use room temperature BAC water
  • Don't use excessive water volume (typically 1-2 mL is sufficient)
  • If gelling occurs, gently warm the vial in your hands and swirl slowly

Storage Guidelines

Lyophilized (Powder)

Store at -20°C (freezer) for long-term storage. Can be kept at 2-8°C (refrigerator) for several months.

Reconstituted

Always refrigerate at 2-8°C. Most peptides remain stable for 4-8 weeks when properly stored.

Research

What is Retatrutide?

An overview of this novel triple-agonist peptide and its significance in metabolic research.

Overview

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that acts as a triple agonist, targeting three different receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This multi-receptor approach distinguishes it from single or dual-agonist compounds.

Mechanism of Action

The triple-agonist mechanism works through complementary pathways:

  • GLP-1:Promotes satiety, slows gastric emptying, and enhances insulin secretion in response to glucose.
  • GIP:Works synergistically with GLP-1 to improve glucose metabolism and may have additional effects on fat tissue.
  • Glucagon:Increases energy expenditure and promotes hepatic lipid oxidation, potentially enhancing metabolic effects.

Research Findings

Phase 2 clinical trials have shown promising results. In the TRIUMPH-2 study, participants receiving the highest dose showed significant changes in body weight over 48 weeks. The compound demonstrated a dose-dependent response across multiple endpoints.

Note: Retatrutide is currently in Phase 3 clinical trials. It is not approved for any medical use. All research compounds should only be used in appropriate research settings.

Research Protocol Considerations

For research applications, Retatrutide is typically administered once weekly via subcutaneous injection. Research protocols often employ a gradual titration approach:

  • Starting doses are typically low to assess tolerance
  • Doses are gradually increased over several weeks
  • Maintenance doses vary based on research objectives
  • Standard reconstitution with bacteriostatic water applies

Need a Specific Protocol?

Browse our complete collection of peptide protocols for detailed dosing and reconstitution guides.